Zhejiang Starry PharmaceuticalLtd Management

Management criteria checks 3/4

Zhejiang Starry PharmaceuticalLtd's CEO is Weiyi Shen, appointed in Jan 2023, has a tenure of 1.33 years. directly owns 0.003% of the company’s shares, worth CN¥147.24K. The average tenure of the management team and the board of directors is 1.4 years and 4.1 years respectively.

Key information

Weiyi Shen

Chief executive officer

CN¥569.6k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	0.003%
Management average tenure	1.4yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Mar 12

Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Feb 28

CEO

Weiyi Shen (43 yo)

1.3yrs

Tenure

CN¥569,600

Compensation

Mr. Weiyi Shen is Vice Chairman of Zhejiang Starry Pharmaceutical Co.,Ltd. since November 01, 2021 and serves as its General Manager since January 2023. He joined the Zhejiang Starry Pharmaceutical Co.,Ltd...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Weiyi Shen	Vice Chairman & GM	1.3yrs	CN¥569.60k	0.0034% CN¥ 147.2k
Junfeng Guo	Financial Director	1.4yrs	CN¥235.50k	no data
Chao Sun	Board Secretary	1.8yrs	CN¥274.20k	no data

1.4yrs

Average Tenure

38yo

Average Age

Experienced Management: 603520's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Weiyi Shen	Vice Chairman & GM	2.5yrs	CN¥569.60k	0.0034% CN¥ 147.2k
Zhifang Sun	Director	4.1yrs	no data	no data
Jin Sheng Hu	Director	no data	CN¥1.26m	17.55% CN¥ 755.4m
Jian Hu	Chairman	1.3yrs	CN¥975.00k	18.03% CN¥ 776.1m
Hong Fan Yang	Independent Director	7.2yrs	CN¥90.00k	no data
Xin Xie	Independent Director	7.2yrs	CN¥90.00k	no data
Wenwen Shen	Independent Director	7.2yrs	CN¥90.00k	no data
Lingqiao Li	Supervisor	4.1yrs	no data	no data
Chaobo Wang	Supervisor	4.1yrs	no data	no data
Meng Tang	Supervisor	4.1yrs	no data	no data
Fangwei Zheng	Chairman of the Supervisory Board	1.3yrs	no data	no data
Hongfei Zhang	Supervisor	1.3yrs	no data	0.0028% CN¥ 120.6k

4.1yrs

Average Tenure

44.5yo

Average Age

Experienced Board: 603520's board of directors are considered experienced (4.1 years average tenure).

Zhejiang Starry PharmaceuticalLtd Management

Management criteria checks 3/4

Key information

Recent management updates

Zhejiang Starry Pharmaceutical Co.,Ltd., Annual General Meeting, May 21, 2024

Less than half of directors are independent

Recent updates

Zhejiang Starry Pharmaceutical Co.,Ltd., Annual General Meeting, May 21, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost

Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥0.15 loss in 3Q 2022)

Price target decreased by 13% to CN¥19.51

Second quarter 2023 earnings released: EPS: CN¥0.066 (vs CN¥0.048 loss in 2Q 2022)

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.19 profit in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.27 profit in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥64.89

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥48.72

Second quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.40 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.19 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥58.80

Investor sentiment improved over the past week

New 90-day low: CN¥59.50

Market bids up stock over the past week

New 90-day low: CN¥66.75

Third quarter earnings released

Zhejiang Starry Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥68.34

First half earnings released

New 90-day high - CN¥91.25

Zhejiang Starry Pharmaceutical Co., Ltd. announced that it has received CNY 671.999962 million in funding from a group of investors

New 90-day high - CN¥86.92

Zhejiang Starry Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age